93.90
-4.07 (-4.15%)
| Penutupan Terdahulu | 97.97 |
| Buka | 95.94 |
| Jumlah Dagangan | 1,757,674 |
| Purata Dagangan (3B) | 2,012,793 |
| Modal Pasaran | 12,316,904,448 |
| Harga / Jualan (P/S) | 11.88 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2026 |
| Margin Keuntungan | -53.82% |
| Margin Operasi (TTM) | -54.33% |
| EPS Cair (TTM) | -3.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -272.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.71 M |
| Pulangan Atas Aset (ROA TTM) | -18.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Guardant Health, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.53% |
| % Dimiliki oleh Institusi | 97.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 180.00 (Leerink Partners, 91.69%) | Beli |
| Median | 130.00 (38.45%) | |
| Rendah | 110.00 (Evercore ISI Group, 17.15%) | Pegang |
| Purata | 133.21 (41.86%) | |
| Jumlah | 13 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 103.24 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 130.00 (38.45%) | Beli | 95.40 |
| BTIG | 20 Feb 2026 | 145.00 (54.42%) | Beli | 103.10 |
| 12 Dec 2025 | 140.00 (49.09%) | Beli | 102.07 | |
| Canaccord Genuity | 20 Feb 2026 | 135.00 (43.77%) | Beli | 103.10 |
| 22 Dec 2025 | 125.00 (33.12%) | Beli | 101.34 | |
| Citigroup | 20 Feb 2026 | 150.00 (59.74%) | Beli | 103.10 |
| 11 Dec 2025 | 135.00 (43.77%) | Beli | 101.38 | |
| Evercore ISI Group | 20 Feb 2026 | 110.00 (17.15%) | Pegang | 103.10 |
| 05 Jan 2026 | 105.00 (11.82%) | Pegang | 101.87 | |
| JP Morgan | 20 Feb 2026 | 130.00 (38.45%) | Beli | 103.10 |
| 15 Dec 2025 | 120.00 (27.80%) | Beli | 102.67 | |
| Leerink Partners | 20 Feb 2026 | 180.00 (91.69%) | Beli | 103.10 |
| 15 Dec 2025 | 155.00 (65.07%) | Beli | 102.67 | |
| Stifel | 20 Feb 2026 | 130.00 (38.45%) | Beli | 103.10 |
| 09 Jan 2026 | 120.00 (27.80%) | Beli | 110.17 | |
| TD Cowen | 20 Feb 2026 | 135.00 (43.77%) | Beli | 103.10 |
| Wells Fargo | 20 Feb 2026 | 125.00 (33.12%) | Beli | 103.10 |
| 15 Dec 2025 | 120.00 (27.80%) | Beli | 102.67 | |
| Baird | 17 Feb 2026 | 120.00 (27.80%) | Beli | 107.11 |
| Guggenheim | 26 Jan 2026 | 135.00 (43.77%) | Beli | 114.74 |
| 05 Jan 2026 | 115.00 (22.47%) | Beli | 101.87 | |
| Mizuho | 17 Dec 2025 | 120.00 (27.80%) | Beli | 97.47 |
| Barclays | 15 Dec 2025 | 120.00 (27.80%) | Beli | 102.67 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |